Highlights

CSL’s FY25 revenue increased 5% YoY to USD 15,558 million, with NPATA rising 14% YoY.
CSL Seqirus highlighted influenza vaccine capabilities, with potential pandemic revenue exceeding USD 3.5 billion.
For FY26, CSL expects revenue growth of 4–5%.

CSL Limited (ASX:CSL) is an ASX-listed company, engaged in the research, advancement, marketing, manufacturing, and distribution of biopharmaceutical products and vaccines. The biotechnology company consists of three divisions: CSL Behring, CSL Seqirus, and CSL Vifor.

Financial Performance

In the financial year 2025 (FY25), CSL has reported total revenue of USD 15,558 million, representing a 5% increase from USD 14,800 million in FY24. Revenue growth was led by CSL Behring, which increased by 6%, CSL Vifor, up 8%, and CSL Seqirus, up 2%. Net profit after tax (NPAT) rose 17% YoY on a constant currency basis, supported by growth in plasma-derived therapies, the iron and nephrology portfolio, cost efficiencies, improved gross margins, and higher free cash flow. Net profit after tax and amortization (NPATA) increased 14% YoY to USD 3,219 million in FY25 from USD 2,907 million in the prior year. Operating cash flow also grew 29% YoY, reaching USD 3,561 million in FY25 compared with USD 2,764 million in FY24.

Business Update

On 5 November 2025, CSL held its Capital Markets Day. The presentation outlined CSL Seqirus’ position in influenza vaccines, highlighting technologies such as cell-based platforms, MF59 adjuvant, and as-mRNA. Key factors discussed included US market recovery, pandemic preparedness, and growth from age expansion and new product introductions. CSL Seqirus’ operational capabilities, industrial network, and customer-focused strategies were noted as supporting revenue growth, projected to exceed USD 3.5 billion in a pandemic scenario.

Key positive and negatives

In FY25, CSL reported a net margin of 20.2%, compared to 18.3% in FY24, and return on equity of 16.4%, up from 15.9% the previous year. During the same period, total operating expenses increased by 3.97% YoY, and the quick ratio was 1.12x below the industry median of 1.77x.

Business Outlook

For FY26, CSL expects group revenue to grow 4–5% year-on-year on a constant currency basis, supported by core CSL Behring therapies, expansion of the nephrology portfolio, and stable performance from CSL Seqirus despite lower contributions from avian flu and COVID-19 vaccines.

Excluding one-off restructuring items, net profit after tax and amortization (NPATA) is projected at AUD 3.45–3.55 billion on a constant currency basis, reflecting 7–10% growth, supported by operational efficiencies, gains in R&D productivity, and ongoing commercial execution.

Share Performance of CSL

CSL’s shares were trading at AUD 176.34 per share on 05 November 2025 with intraday
loss of 0.37%. CSL’s stock down by 34.59% in last three months as well as down by
27.42% over the six months and declined 37.90% over the past year. CSL’s 52 week
high is AUD 290.315, recorded on 08 January 2025 and 52-week low is AUD 168.0,
recorded on 29 October 2025.

Support and Resistance Summary

Note 1: Past performance is neither an Indicator nor a guarantee of future performance.

Note 2: The reference date for all price data, and currency, is 05 November 2025. The reference data in this report has been partly sourced from EODHD/Others.

Technical Indicators Defined:

Support: A level at which the stock prices tend to find support if they are falling, and a downtrend may take a pause backed by demand or buying interest. Support 1 refers to the nearby support level for the stock and if the price breaches the level, then Support 2 may act as the crucial support level for the stock.

Resistance: A level at which the stock prices tend to find resistance when they are rising, and an uptrend may take a pause due to profit booking or selling interest. Resistance 1 refers to the nearby resistance level for the stock and if the price surpasses the level, then Resistance 2 may act as the crucial resistance level for the stock.